Patent Application
20080317734
The present disclosure relates to compositions for providing treatment, restoration, and maintenance, of an individual's cells by providing readily absorbable nutrients that the individual lacks.
Nutraceutical formulations are personalized to address an individual's nutrient deficiencies. Growth factors and high doses of inefficiently absorbed nutrients are nanoencapsulated and delivered orally to improve the function, health, and appearance of the individual.
According to a feature of the present disclosure, a method is disclosed comprising providing a personalized nutrient screening to identify nutrient deficiencies, and providing a nutraceutical with at least one active ingredient to address the deficiencies. The active ingredient comprises at least one vitamin, mineral, growth factor, peptide fragment of growth factors, antioxidant, protease, natural extract, or amino acid.
According to a feature of the present disclosure, a composition is disclosed comprising a nutraceutical formulation having at least one active ingredient. The nutraceutical formulation is formulated to address at least one nutrient deficiency, the nutrient deficiency determined by at least one personalized nutrient screen process. Moreover, the active ingredient further comprises at least one vitamin, mineral, growth factor, peptide fragment of growth factors, antioxidant, protease, natural extract, or amino acid.
According to feature of the present disclosure, a method comprising providing a personalized nutrient screening to identify nutrient deficiencies, correlating the observed deficiencies to a database of growth factors to determine a set of growth factors that may be administered to overcome the deficiencies, and providing a nutraceutical with at least one active ingredient to address the deficiencies. The active ingredient comprises at least one vitamin, mineral, growth factor, peptide fragment of growth factors, antioxidant, or amino acid and the nutraceutical is prepared from a base nutraceutical formulation and a plurality of deficiency-based nutraceutical formulations tailored to address various nutrient deficiencies.
The above-mentioned features and objects of the present disclosure will become more apparent with reference to the following description taken in conjunction with the accompanying drawings wherein like reference numerals denote like elements and in which:
In the following detailed description of embodiments of the invention, reference is made to the accompanying drawings in which like references indicate similar elements, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that other embodiments may be utilized and that logical, mechanical, biological, electrical functional, and other changes may be made without departing from the scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims. As used in the present disclosure, the term “or” shall be understood to be defined as a logical disjunction and shall not indicate an exclusive disjunction unless expressly indicated as such or notated as “xor.”
As used in the present disclosure, the term “active ingredient” shall be defined as a component of a nutraceutical that interacts with or effects changes in tissues, cells, biological pathways, or native molecules.
As used in the present disclosure, the term “nutraceutical” shall be defined as a ingested substance having at least one active ingredient designed to improve the health of an organism.
The present disclosure relates to nutraceuticals having nanosome encapsulated growth factors, vitamins, minerals, amino acids, antioxidants, and other active ingredients to increase the health and function of an individual, as well as reverse the effects of aging with respect to appearance.
The body comprises a complex system of biological pathways. A single base pair mutation, also known as small nucleotide polymorphisms, or other mutations may cause a breakdown or an inefficiency in a biological pathway that results in a deficiency in the production of growth factors or uptake of nutrients.
According to the present disclosure, nutraceuticals containing active ingredient are disclosed. The nutraceutical contains at least one or more biologically active ingredients based on the desired function of the nutraceutical. The ingredients may be encapsulated in nanosomes depending on the susceptibility of each active ingredient to degradation within the nutraceutical. Multiple ingredients may be encapsulated together within single nanosomes or the ingredients may be individually encapsulated. Generally, the active ingredients are mixed in a straightforward manner with the base nutraceutical.
The active ingredients include, but are not limited to, proteins, peptides, proteases, vitamins, minerals, fatty acids, amino acids, nucleic acids, and anti-oxidants. In particular, the proteins include growth factors such as EGF, IGF-1, bFGF, aFGF, KGF, TGF-β3, Thymosin β4, and VEGF. Additionally, thioredoxin, peptide TGP2, copper peptide, ascorbic acid, kojic acid, glycolic acid, hyaluronic acid, arbutin, coenzyme Q10, licorice extract, oryza, sative hull extract, and green tea extract may also be used.
The active ingredients may include chemically synthesized peptides which mimic the function of naturally produced growth factors in a human body.
Other ingredients may be added to the nutraceutical that do not have biologically active properties. These ingredients include, for example, moisturizing ingredients, ingredients that impart desired properties such a UV resistance, and ingredients that impart the characteristics of the nutraceutical, such as color, consistency, texture, viscosity, and smell.
According to various embodiments, the nutraceuticals may be in various embodiments and forms including food additives, pills and tablets, encapsulated gels, elixers, beverages, mixable powders, etc. According to embodiments, the nutraceutical comprises a patch that releases active ingredients encapsulated in nanosomes through the skin. According to embodiments, the nutraceuticals include foaming cleansers, moisturizers, toners, day creams, night creams, eye creams, lotions, sun screens and sun blocks, serums, and healing creams that are applied on the skin.
Desired functions of the nutraceuticals include, modulating cell metabolism and function, ensuring an adequate supply of nutrients actually being absorbed into the cells, and prevent premature aging, according to embodiments.
According to embodiments, the uptake of nutrients is improved by packaging the nutrients into nanosomes, which are readily absorbed through the gastrointestinal tract and the contents thereof delivered intracellularly. Because many nutrients are water soluble, nutrients are inefficiently absorbed through the gastrointestinal tract. By encapsulating water soluble nutrients, growth factors, etc., into nanosomes, they may be absorbed through the gastrointestinal tract and into the target cells. Similarly, fat soluble nutrients and growth factors are storable and deliverable using nanosomes as well.
According to embodiments illustrated in
Nanosomes may be desirable, according to embodiments, because they improve bioavailability of the active ingredients encapsulated within them. Bioavailability is increased because more active ingredient is actually delivered to its target Moreover, nanosomes readily cross through the gastrointestinal membrane, thereby effectively transporting the active ingredients into the blood stream. Additionally, because the bioavailability is increased, less active ingredient must be used, which reduces the costs associated with producing and delivering active ingredients to effect a result. Because the active ingredients encapsulated in the nanosome are protected from the environment me active ingredients have a longer shelf life and are more stable on average than those not encapsulated. Importantly, active ingredients encapsulated within a nanosome can undergo pasteurization without destroying the active ingredient in the process.
Most importantly, however, the nanosome protects the active ingredients from oxidation, hydrolysis, reduction, and enzymatic reaction, thereby allowing the active ingredient to arrive at its target is an active state. Finally, nanosome encapsulation, masks odor and taste of the active ingredients, making them more pleasing to those who use the active ingredients.
As such, the nanosome encapsulated nutraceuticals of the present disclosure, provide an effective platform, to children and pets. Children, in particular often object to the consistency and flavor of medications or vitamins and refuse to take them. Nanosomes masks odors and flavors thereby making the active ingredients more palatable.
The growth factors of the present disclosure may be encapsulated in nanosomes, and the nanosomes put into a delivery vehicle. Thus, they will be effectively delivered, through the skin, or into the blood stream via the gastrointestinal tract. Thereafter, the nanosomes may be absorbed into cells by fusing with cellular membranes or via endocytosis, for example.
Nanosomes are excellent tools for delivering pharmacological active ingredients through the skin or the digestive tract directly to the cell without exposing the active ingredients to degradation events prior to delivery. Additionally, nanosomes allow active ingredients that would, otherwise only inefficiently arrive at the target cells, for example, water soluble active ingredient applied topically. Thus, in combination, with the novel active ingredients disclosed herein, nanosomes provide a delivery device to efficiently cause the active ingredients to be delivered intracellularly.
According to embodiments and as illustrated in
According to embodiments and as illustrated in
For example, where a gene mutation interrupts a biological process or reduces the efficiency of a process such that a given growth factor is inefficiently produced, providing the growth factor from an external source bypasses the genetic anomaly allowing the cells to uptake the nutrient at the same level as is within a normal range in a population. Similarly, where the a nutrient uptake is inefficient, for example, due to a breakdown in the uptake biological processes, an abundance of that nutrient may be provided as a “brute force” mechanism to overcome the inefficiency. Delivery by nanosomes provides a platform for delivery into cells without degradation, inactivation, oxidation, or reduction of the active ingredients.
According to embodiments, tissue, blood, and serum tests measuring quantities of an individual's nutrients are used to provide information on deficiencies that may be associated with an individual's diet and uptake of nutrients. Diet and nutrient intake is one of the many factors that influence the nutritional status of an individual. Insufficient intake or uptake of specific nutrients generally results in a deficiency of that nutrient,
According to embodiments, the nutritional deficiency assay is an assay measuring levels of accumulation of the nutrient in lymphocytes of the individual. Generally, an intracellular function assay is used and comprises the steps of collecting lymphocyte cells, isolating the cells from other whole blood components, and maintaining the cells in culture during the assay. The lymphocytes collected have a 4- to 6-month lifespan and are generally in a resting state in terms of cell division. The resting lymphocytes are stimulated to undergo cell division and grow in culture. The degree of growth that, the lymphocytes are able to maintain following stimulation is directly related to the nutrient levels accumulated in the lymphocytes. From, the lymphocyte degree of growth, a functional intracellular analysis of nutrient status maybe obtained.
According to embodiments, the nutrient targeted in the nutritional deficiency assay is selected from vitamins, minerals, amino acids, antioxidants, and metabolites. According to embodiments, as shown in Table 1, the nutrient is a vitamin such as vitamin A, B1, B2, B3, B6, B12, D, E, biotin, folate, and panothenate; minerals such as calcium, magnesium, selenium, and zinc; an amino acid such as asparagine, carnitine, glutamine, and serine; an antioxidant selected from coenzyme Q10, glutathione, and cysteine; or a metabolite such as lipoic acid, oleic acid, choline, inositol, fructose, glucose, and insulin. Other vitamins, minerals, antioxidants, and nutrients may also be targeted in the nutritional deficiency assay, as would be known and understood by artisans.
According to embodiments, genetic testing is used to provide information regarding an individual's health based on the individual's genetic conditions. An individual's inherited health risks and potential health problems may be assessed through the genetic testing. More importantly, correlations maybe drawn to nutritional deficiencies based on observed genetic mutations. Thus, genetic assays may lead to information regarding the cause of nutrient deficiencies or nutritional deficiencies that are unobserved in other assay method. This allows for the development of a suitable diet, lifestyle, and supplement regimen that matches the unique health risks of an individual's body.
In one embodiment, the genetic variation assay is an assay searching for single nucleotide polymorphisms (SNPs) in the gene. A SNP is a natural variation or change in a single nucleotide base pair of a gene, which may affect the way an individual's body responds to certain stimuli such as damage, infection, or even food intake. Cells are collected and select segments of the genetic code are tested for SNPs. The cells are preferably collected from a mouth rinse procedure, but can also be collected from a blood sample or other methods. The genetic test evaluates SNPs that may lead to health problems when influenced by other external and environmental factors. Based on the genetic test results, a customized treatment plan may be developed.
Functional assessment, tests may also be conducted to monitor if an individual's personalized health regimen has an impact on the individual's genetic risks. By evaluating how the individual's body responds to treatment, functional assessment tests may be used to ensure that environmental factors, such as hormones and nutrients, are in a state of optimal balance that minimizes the individual's in-born genetic health risks.
According to embodiments, the gene assayed is at least one of TNFa, IL-6, IL-1βSOD1, SOD2, CAT, EPHX1, GPX1, MnSOD2, p53, IGF, TGFβ1, MMP, EGF, ELA2, VEGF, bFGF, APOE, MTHFR, and ACE. Genes evaluated include but are not limited to the genes shown in the following Table 2.
According to embodiments, the method for providing a health regimen comprises formulating at least one nutraceutical based upon at least one of the nutritional deficiency assay result and genetic variation assay result. Active ingredients include vitamins, minerals, growth factors, antioxidants, metabolites, amino acids, nucleic acids, and other biomolecules, etc, to address specific nutrient deficiencies of the individual if a nutrient is inefficiently absorbed, higher doses of the nutrient may correct the deficiency in a “brute force” manner, or the machinery for uptake of the nutrient may be repaired to increase uptake, according to embodiments.
According to embodiments, a health regimen Is provided for an individual. The health regimen comprises: (1) at least one nutritional deficiency assay targeting at least one nutrient of the individual wherein the nutritional deficiency assay produces a nutritional deficiency assay result; (2) at least one genetic variation assay targeting at least one gene of the individual, wherein the genetic variation assay produces a genetic variation assay result; and (3) at least one health recommendation to the individual, wherein the health recommendation is based upon at least one of the nutritional deficiency assay result and genetic variation assay result.
According to embodiments, each customized personal formula may be selected from a preproduced formulation of active ingredients. These “custom” formulas are recommended to each individual based on their unique nutritional needs. The individual formula may be selected from a library of nutraceutical formulas based on observed deficiencies and needs across a population.
The library is created by collecting a database of patients who have gone through a given testing process. Their test results determine the nutritional deficiencies of each individual. After statistical analysis of their deficiencies across the population of patients tested, a pattern is determined. The deficiency patterns may be correlated to gene mutations, hormonal and neurotransmitter imbalances, and phenotypic traits, for example to further identify and fine tune the assay process.
According to embodiments, a statistical approach for determining deficiencies applies a normal curve to the population. Those having nutritional deficiencies will be observed outside the confidence levels of the normal curve. As the statistical analysis is applied for larger populations, patterns will emerge wherein certain deficiencies are linked, for example a deficiency in the uptake of calcium with a deficiency in vitamin D. Thus, formulations may be designed to address each deficiency from the standpoint of providing all of the necessary active ingredients to address a given deficiency.
According to embodiments and to the extent that patterns may be determined, formulations are preproduced with a formulation of active ingredients to address identified deficiencies. According to embodiments, the preproduced formulations may be added to a base nutraceutical, for example an ingestible tablet. If multiple deficiencies are observed, multiple formulations may be added to the base nutraceutical provided no one active ingredient is dosed at a dangerous level.
Similarly, more general formulas are formulated, according to embodiments, to less specifically address with deficiencies. Users may undergo the assay process to accurately identify deficiencies or may consult another source to determine potential deficiencies, such as a doctor or a table detailing deficiencies based on diet. The user then obtains one or more preformulated nutraceuticals to address the deficiencies, wherein the preformulated nutraceutical comprises a personal regimen only insofar as the selected preformulation includes the necessary ingredients to treat the deficiencies. For example, a set of formulations may be devised as follows, with dosages as shown in Tables 1-4:
Formulation A: High dose vitamins+High dose anti-oxidants+RDA dose minerals
Formulation B: High dose vitamins+RDA dose anti-oxidants+RDA dose minerals
Formulation C: RDA dose vitamins+High dose anti-oxidants+RDA dose minerals
Formulation D: RDA dose vitamins+High dose anti-oxidants+High dose minerals
Formulation E: High dose vitamins+High dose anti-oxidants+Amino Acids
Formulation F: High dose vitamins+RDA dose anti-oxidants+Amino Acids
Formulation G: RDA dose vitamins+ RDA dose anti-oxidants+High dose minerals+Amino Acids
According to other embodiments, static nutraceutical formulations are similarly appropriate with emphasis on the end result of each formulation. For example, a nutraceutical may be provided for elderly users designed to restore elastins and collagens in the skin, thereby reducing lines and wrinkles by improving the “tightness” of the skin.
While the apparatus and method have been described in terms of what are presently considered to be practical embodiments, it is to be understood that the disclosure need not be limited to the disclosed embodiments. It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar structures. The present disclosure includes any and all embodiments of the following claims.
This application claims the benefit of and priority to U.S. utility patent application Ser. No. 12/765,977 filed 20 June 2007, entitled “Personalized Nutrient Deficiency Assay” the contents of which are incorporated by reference herein in its entirety.
